Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1

Status

Completed 5Recruiting 4Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Cladribine × Clear all
NCT07053020 2026-03-04

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
58 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡